RegenxBio Inc. - EP4096631A1 Treatment of Mucopolysaccharidosis II With Recombinant Human Iduronate-2-Sulfatase Produced by Human Neural or Glial Cells

The European Patent Office published application EP4096631A1 for RegenxBio Inc., covering a therapeutic method for Mucopolysaccharidosis II (a rare lysosomal storage disorder) using recombinant human iduronate-2-sulfatase enzyme produced by engineered human neural or glial cells. The application is classified under multiple IPC categories including A61K (preparations for medical purposes), C12N (microorganisms/enzymes), and G01N (measuring/testing). Patent kind code A1 indicates the publication includes the search report.

Affected parties in the biotech and rare-disease pharmaceutical space should note this patent filing as it may affect freedom-to-operate considerations for competing gene therapy or enzyme replacement approaches targeting MPS II. No immediate compliance obligations arise from this publication alone; the patent application enters the examination phase and any granted patent would confer exclusivity upon issuance.